• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用常规临床参数对接受细胞减灭术的恶性胸膜间皮瘤患者进行分层以预测生存。

Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.

机构信息

Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia; Curtin Medical School, Curtin University, Perth, Australia.

Chris O'Brien Lifehouse, Sydney, Australia; Asbestos Diseases Research Institute, Sydney, Australia.

出版信息

J Thorac Oncol. 2019 Feb;14(2):288-293. doi: 10.1016/j.jtho.2018.10.005. Epub 2018 Oct 24.

DOI:10.1016/j.jtho.2018.10.005
PMID:30366103
Abstract

INTRODUCTION

Malignant pleural mesothelioma (MPM) is an uncommon cancer with a poor prognosis and heterogeneous survival. Surgery for MPM is offered in some specialist centers to highly selected patients. A previously described classification and regression tree (CART) model stratified survival in unselected MPM patients using routinely collected clinical data. This study aimed to examine the performance of this CART model on a highly selected surgical population.

METHODS

Data were collected from subjects undergoing cytoreductive surgery for MPM from specialist centers in Hyõgo, Japan, and Sydney, Australia, between 1991 and 2016. The CART model was applied using the combination of clinical variables to stratify subjects into risk groups (1 through 4); survival characteristics were then compared.

RESULTS

Two hundred eighty-nine cases were included (205 from Australia, 84 from Japan). Overall median survival was 34.6 (interquartile range: 17.5-56.1) months; median age was 63.0 (interquartile range: 57.0-67.8) years, and 83.0% (n = 240) were male. There were no clinically meaningful differences between the two cohorts. Survival across the four risk groups was significantly different (p < 0.0001); the model stratified survival well with a Harrell's concordance statistic of 0.62 (95% confidence interval: 0.57-0.66) at 36 months. The group with the longest survival (median, 82.5 months) had: no weight loss, hemoglobin > 153 g/L and serum albumin > 43 g/L at time of referral to the surgical center.

CONCLUSIONS

Using routinely available clinical variables, the CART model was able to stratify surgical patients into risk groups with statistically different survival characteristics with fair to good performance. Presence of weight loss, anemia, and low albumin should confer caution when considering surgical therapy for MPM.

摘要

简介

恶性胸膜间皮瘤(MPM)是一种罕见的癌症,预后不良,生存情况存在异质性。一些专科中心会为高度选择的患者提供 MPM 手术。之前描述的分类和回归树(CART)模型使用常规收集的临床数据对未经选择的 MPM 患者进行分层,以评估其生存率。本研究旨在研究该 CART 模型在高度选择的手术人群中的表现。

方法

从 1991 年至 2016 年,在日本兵库县和澳大利亚悉尼的专科中心接受减瘤性手术治疗的 MPM 患者中收集数据。使用临床变量组合应用 CART 模型将患者分层为风险组(1-4 组);然后比较生存特征。

结果

共纳入 289 例(澳大利亚 205 例,日本 84 例)。总体中位生存时间为 34.6(四分位距:17.5-56.1)个月;中位年龄为 63.0(四分位距:57.0-67.8)岁,83.0%(n=240)为男性。两个队列之间没有明显的临床差异。四个风险组的生存情况差异有统计学意义(p<0.0001);模型在 36 个月时具有良好的分层效果,Harrell 一致性指数为 0.62(95%置信区间:0.57-0.66)。生存时间最长的组(中位生存时间为 82.5 个月)在转诊至外科中心时无体重减轻、血红蛋白>153g/L 和血清白蛋白>43g/L。

结论

使用常规临床变量,CART 模型能够将手术患者分层为具有统计学差异的生存特征的风险组,表现为中等至良好。体重减轻、贫血和低白蛋白的存在提示在考虑 MPM 手术治疗时应谨慎。

相似文献

1
Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.使用常规临床参数对接受细胞减灭术的恶性胸膜间皮瘤患者进行分层以预测生存。
J Thorac Oncol. 2019 Feb;14(2):288-293. doi: 10.1016/j.jtho.2018.10.005. Epub 2018 Oct 24.
2
A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.基于决策树分析的恶性胸膜间皮瘤预后新型临床预测模型
J Thorac Oncol. 2016 Apr;11(4):573-82. doi: 10.1016/j.jtho.2015.12.108. Epub 2016 Jan 8.
3
Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.使用常规临床参数对合并恶性胸腔积液的恶性胸膜间皮瘤患者进行生存分层的预测模型。
Thorac Cancer. 2021 Dec;12(24):3304-3309. doi: 10.1111/1759-7714.14202. Epub 2021 Oct 26.
4
Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.采用递归分区分析对恶性胸膜间皮瘤预后进行分层。
Lung. 2014 Feb;192(1):191-5. doi: 10.1007/s00408-013-9516-y. Epub 2013 Oct 20.
5
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.间皮瘤血清和胸腔积液中可溶性间皮素相关肽水平升高。
Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272. doi: 10.1016/j.athoracsur.2007.07.042.
6
Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.64例恶性胸膜间皮瘤患者行胸膜切除术后的发病率、死亡率、平均生存期以及组织学对生存期的影响。
Int J Surg. 2008 Aug;6(4):293-7. doi: 10.1016/j.ijsu.2008.04.004. Epub 2008 May 1.
7
[Surgical therapy of malignant pleural mesothelioma].[恶性胸膜间皮瘤的外科治疗]
Chirurg. 2016 May;87(5):455-66. doi: 10.1007/s00104-016-0186-1.
8
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.改善恶性胸膜间皮瘤手术治疗后的生存结果:澳大利亚一家机构的经验
Ann Thorac Cardiovasc Surg. 2011;17(3):243-9. doi: 10.5761/atcs.oa.10.01572.
9
Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.恶性胸膜间皮瘤姑息性胸膜切除术/胸膜剥脱术:手术结果
Eur J Cardiothorac Surg. 1997 Feb;11(2):210-3. doi: 10.1016/s1010-7940(96)01008-1.
10
Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group.恶性胸膜间皮瘤手术技术统一定义建议:国际肺癌研究协会国际分期委员会和国际间皮瘤兴趣小组的共识报告。
J Thorac Oncol. 2011 Aug;6(8):1304-12. doi: 10.1097/JTO.0b013e3182208e3f.

引用本文的文献

1
Assessment of risk factors related to early occurrence of deep vein thrombosis after TBI using nomogram model.使用列线图模型评估与创伤性脑损伤后早期发生深静脉血栓形成相关的危险因素。
Sci Rep. 2025 Aug 11;15(1):29313. doi: 10.1038/s41598-025-15287-z.
2
Diffuse Pleural Mesothelioma: A Challenge in Early Diagnosis.弥漫性胸膜间皮瘤:早期诊断的挑战
Cureus. 2024 Dec 2;16(12):e74998. doi: 10.7759/cureus.74998. eCollection 2024 Dec.
3
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
国际肺癌研究协会胸膜间皮瘤分期项目:胸膜间皮瘤预后因素的更新模型。
J Thorac Oncol. 2023 Dec;18(12):1689-1702. doi: 10.1016/j.jtho.2023.08.005. Epub 2023 Aug 9.
4
Contemporary issues in the surgical management of pleural mesothelioma.胸膜间皮瘤的外科治疗的当代问题。
J Surg Oncol. 2023 Feb;127(2):343-354. doi: 10.1002/jso.27152.
5
Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的临床、实验室、组织学、影像学和代谢特征及预后
Medicina (Kaunas). 2022 Dec 19;58(12):1874. doi: 10.3390/medicina58121874.
6
The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的治疗现状。
Curr Oncol Rep. 2022 Nov;24(11):1413-1423. doi: 10.1007/s11912-022-01302-3. Epub 2022 Jun 3.
7
Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.使用常规临床参数对合并恶性胸腔积液的恶性胸膜间皮瘤患者进行生存分层的预测模型。
Thorac Cancer. 2021 Dec;12(24):3304-3309. doi: 10.1111/1759-7714.14202. Epub 2021 Oct 26.
8
Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的流行病学与临床特征
Cancers (Basel). 2021 Aug 20;13(16):4194. doi: 10.3390/cancers13164194.
9
Malignant Pleural Mesothelioma: Time Is Running Out.恶性胸膜间皮瘤:时间紧迫。
J Clin Med. 2021 Feb 8;10(4):648. doi: 10.3390/jcm10040648.
10
Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation.恶性胸膜间皮瘤的生物标志物——关于炎症的新观点
Cancers (Basel). 2021 Feb 6;13(4):658. doi: 10.3390/cancers13040658.